A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system

Transfusion

Volumn 46, Issue 12, 2006, Pages 2100-2108

  Burnouf, Thierry ^a   Goubran, Hadi Alphonse ^b   Radosevich, Miryana ^b   Sayed, Makram A ^b   Gorgy, George ^b   El Ekiaby, Magdy ^b  

^a HUMAN PROTEIN PROCESS SCIENCES   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CASTOR OIL; DETERGENT; FIBRINOGEN; IMMUNOGLOBULIN; PLASMA PROTEIN; PROTEIN; PROTEIN C; PROTEIN S; PROTEINASE INHIBITOR; REAGENT; SOLVENT; TRIBUTYL PHOSPHATE; TYLOXAPOL; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD BANK; BLOOD CLOTTING TEST; BLOOD COMPONENT; CENTRIFUGATION; CHEMICAL PROCEDURES; COST BENEFIT ANALYSIS; DISPOSABLE BAG SYSTEM; DISPOSABLE EQUIPMENT; HUMAN; PLASMA; PLASMA TRANSFUSION; QUALITY CONTROL; TECHNOLOGY; VIRUS ENVELOPE; VIRUS INACTIVATION;

BLOOD BANKS; BLOOD PRESERVATION; BLOOD PROTEINS; BLOOD TRANSFUSION; HUMANS; OCTOXYNOL; PHOSPHORIC ACID ESTERS; VIRUS DISEASES; VIRUS INACTIVATION;

EID: 33751360613     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.01035.x     Document Type: Article

References (44)

1. Klein HG. Pathogen inactivation technology: cleansing the blood supply. J Intern Med 2005;257:224-37.
2. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005;19:110-26.
3. Horowitz B, Bonomo R, Prince AM, et al. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992;79:826-31.
4. Horowitz B, Lazo A, Grossberg H, et al. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998;74(Suppl 1):203-6.
5. Piet MP, Chin S, Prince AM, et al. The use of tri(n-butyl) phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation. Transfusion 1990;30:591-8.
6. Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 1992;63:178-85.
7. Piquet Y, Janvier G, Selosse P, et al. Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 1992;63:251-6.
8. Pooled plasma, solvent/detergent treated. Summary of basis for approval 93-0253 and 97-0141. Rockville (MD): Food and Drug Administration; 1998.
9. Guidelines on viral inactivation and removal procedures intended to assure the viral safety of human blood plasma products. Geneva: World Health Organization; 2003. p. 1-72.
10. Hellstern P, Larbig E, Walz GA, et al. Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients. Infusionsther Transfusionsmed 1993;20(Suppl 2):16-8.
11. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999;39:1227-34.
12. Freeman JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang 1998;74(Suppl 1):225-9.
13. Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/detergent- treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000;79:161-7.
14. Haubelt H, Blome M, Kiessling AH, et al. Effects of solvent/detergent- treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 2002;82:9-14.
15. Beck KH, Mortelsmans Y, Kretschmer VV, et al. Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed 2000;27:144-8.
16. Solheim BG, Rollag H, Svennevig JL, et al. Viral safety of solvent/detergent-treated plasma. Transfusion 2000;40:84-90.
17. Baudoux E, Margraff U, Coenen A, et al. Hemovigilance: clinical tolerance of solvent-detergent treated plasma. Vox Sang 1998;74(Suppl 1):237-9.
18. Inbal A, Epstein O, Blickstein D, et al. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993;4:599-604.
19. Tollofsrud S, Noddeland H, Svennevig JL, et al. Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 2003;29:1736-43.
20. Harrison CN, Lawrie AS, Iqbal A, et al. Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:756-8.
21. Evans G, Llewelyn C, Luddington R, et al. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol 1999;21:119-23.
22. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 1994;272:1210-4.
23. Koenigbauer UF, Eastlund T, Day JW. Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 2000;40:1203-6.
24. Mortelmans Y, Beck KH, Kretschmer V. [Preliminary results of a prospective randomized clinical study on the comparison of solvent- and detergent-inactivated plasma (SDP-TNBP/Triton X-100) and untreated fresh-frozen plasma]. Beitr Infusionsther Transfusionsmed 1994;32:419-21.
25. Yarranton H, Lawrie AS, Purdy G, et al. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004;14:39-44.
26. Doyle S, O'Brien P, Murphy K, et al. Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 2003;14:283-7.
27. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998;74(Suppl 1):219-23.
28. Flamholz R, Jeon HR, Baron JM, Baron BW. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apheresis 2000;15:169-72.
29. Yarranton H, Cohen H, Pavord SR, et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-85.
30. de Jonge J, Groenland TH, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP). Anesth Analg 2002;94:1127-31.
31. Clauss A. Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957;17:237.
32. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991;60:207-13.
33. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002;42:1302-7.
34. Corbin F 3rd. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol 2002;76(Suppl 2):253-7.
35. Goubran HA, Burnouf T, Radosevich M. Virucidal heattreatment of single plasma units: a potential approach for developing countries. Haemophilia 2000;6:597-604.
36. Burnouf T, Radosevich M, El-Ekiaby M, et al. Nanofiltration of single plasma donations: feasibility study. Vox Sang 2003;84:111-9.
37. Burnouf-Radosevich M, Burnouf T, Huart JJ. A pasteurized therapeutic plasma. Infusionsther Transfusionsmed 1992;19:91-4.
38. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000;14:94-110.
39. Hellstern P. Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004;11:346-50.
40. Keeling DM, Luddington R, Allain JP, et al. Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method. Br J Haematol 1997;96:194-7.
41. Allford SL, Harrison P, Lawrie AS, et al. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000;111:1215-22.
42. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood 1999;94:3922-7.
43. Snyder EL, Dodd RY. Reducing the risk of blood transfusion. Hematology Am Soc Hematol Educ Program 2001:433-42.
44. Burnouf T, Goubran H, Radosevich M, et al. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centers using a disposable bag system. Vox Sang 2006;91:56-62.